The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

IRF4 addiction in multiple myeloma

Arthur L. Shaffer, N. C. Tolga Emre, Laurence Lamy et al. · Nature · 2008 · 728 citations · Full text

Medicine, Cancer Biology, Oncology +11

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi et al. · Blood · 2011 · 602 citations · Full text

Medicine, Oncology, Pharmacology +9

BATF–JUN is critical for IRF4-mediated transcription in T cells

Peng Li, Rosanne Spolski, Wei Liao et al. · Nature · 2012 · 465 citations

Life Sciences, Immunology, Molecular Biology +8

Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene.

Yan Lavrovsky, Michal L. Schwartzman, R D Levere et al. · Proceedings of the National Academy of Sciences · 1994 · 402 citations

Life Sciences, Biochemistry, Molecular Biology +16